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Abstract
Purpose—Evaluate how well three different patient-reported outcomes (PROs) measure 
individual change.
Methods—214 patients (from two sites) initiating first or new chemotherapy for any stage of 
breast or gastrointestinal cancer participated. The 13-item FACIT–Fatigue scale, a 7-item 
PROMIS® Fatigue Short-Form (PROMIS 7a), and the PROMIS® Fatigue computer adaptive test 
(CAT) were administered monthly online for six months. Reliability of measured change was 
defined, under a population mixed effects model, as the ratio of estimated systematic variance in 
rate-of-change to the estimated total variance of measured individual differences in rate-of-change. 
Precision of individual measured change, the standard error of measurement (SEM) of change, 
was given by the square root of the rate-of-change sampling variance. Linear and quadratic models 
were examined up to 3 and up to 6 months.
Results—A linear model for the reliability of measured change showed the following by 6 and 
by 3 months, respectively: PROMIS CAT (0.363 and 0.342); PROMIS SF (0.408 and 0.533); 
FACIT (0.459 and 0.473). Quadratic models offered no noteworthy improvement over linear 
models. Both reliability and precision results demonstrate the need to improve the measurement of 
intra-individual change.
Conclusions—These results illustrate the challenge of reliably measuring individual change in 
fatigue with a level of confidence required for intervention. Optimizing clinically useful 
measurement of intra-individual differences over time continues to pose a challenge for PROs.
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Introduction
Fatigue is a common cancer-related symptom and adverse event reported by individuals 
treated for cancer [1,2]. The importance of monitoring fatigue levels in cancer patients and 
survivors was recently emphasized in a new set of American Society of Clinical Oncology 
(ASCO) guidelines for screening, assessing, and managing fatigue [1]. The ASCO 
Guidelines indicated that most cancer patients experience some degree of fatigue during 
treatment and about 30% of patients have persistent fatigue. The value of routine, in-clinic 
assessment of multiple patient-reported outcomes (PROs), including screening for cancer-
related symptoms such as fatigue is of great interest [3-7]. Routine use of PROs in clinical 
settings potentially allows for 1) monitoring effects of treatment on individual patients as 
well as 2) assisting in disease management, both of which allow for the direct inclusion of 
patient experience into the care environment [7-9]. Fatigue screening approaches are 
recommended in the 2014 ASCO Guidelines as routine practice, beginning at diagnosis and 
moving to more comprehensive assessment techniques for patients whose fatigue reflects 
moderate to severe levels; at this level, more clinical and laboratory evaluation as well as 
more comprehensive patient-reported measures are recommended.
Nunnally's text, Psychometric Theory, [10] is recognized as a key source for instrument 
development; a reliability of 0.95 was recommended if decisions are to be made regarding a 
single test score (page 246). Either a reliability level of 0.95 or ≥ 0.90 has continued to be 
recognized by instrument developers for use of PRO scores at the individual level 
[4,11-13].The precision of PRO measures used in oncology clinical settings has been 
debated for a number of years [11,12,14-17]. Although fixed-length and CAT (variable 
length) measures developed using item response theory (IRT) have been described as more 
precise (per item) than commonly used PRO measures based on classical test theory criteria 
[8,9,18-20], few studies have been published supporting use of CAT measures (or any other 
measures) in terms of their reliable responsiveness to individual change. Lai et al. [19] have 
demonstrated such better precision of individual status with a CAT measure, but with respect 
to a single time point. The most commonly used measure of reliability has been coefficient 
alpha [21] but this measure uses item homogeneity to estimate systematic variation between 
individuals at static time points, not systematic differences in how individuals change 
[17,22]. Important psychometric criteria for measured change in fatigue and other PROs, 
such as the precision of estimates of individual change, have been described 
[10,12,14-17,22,23]. Stringent reliability and precision criteria are just as important for 
measurement of individual change, but rate-of-change has seldom been considered as a 
measurement.
Hahn et al. [15] compared measurement error for PRO (e.g., SF-36 scales) and clinical (e.g., 
systolic and diastolic blood pressure) measures of patient status and concluded that these 
two types of measures were comparable with respect to measurement criteria and that within 
both types of measures, one finds high, good, and low reliability. Many clinical status 
measures show considerable measurement error (e.g., tumor size measurements and systolic 
hypotension); yet these measures are used consistently in medical care and research. Hahn et 
al. suggested that given this widespread variation in measurement quality, use of both types 
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of measures can complement each other (i,e., both are important for arriving at an accurate 
description of patient status) [15]. Methods addressing measured change at the individual 
patient level, such as those described in this report, need to be applied to longitudinal 
assessments using clinical measures. Measurement of trajectories of change is challenging 
regardless of the property being measured. Both clinical and PRO measures should be 
subjected to more research regarding tracking and interpreting change for individual 
patients.
In this pilot study, we sought to compare three measures of change in fatigue: IRT-based 
PROMIS Fatigue CAT [8,9,24,25] and the 7-item PROMIS Fatigue 7a Short-Form, hereafter 
referred to as the PROMIS 7a [19]; and the FACIT-Fatigue [26,27], a classical test theory-
based, legacy measure of fatigue. This report compares the quality of change measurement 
for the three measures in a sample of patients undergoing chemotherapy treatment for cancer 
over a six month period.
Methods
Study design and sample
Two hundred fourteen patients with breast or gastrointestinal (GI) cancers were enrolled in 
this study through the Seattle Cancer Care Alliance (SCCA, Fred Hutchinson Cancer 
Research Center, Seattle, WA) and the Lombardi Comprehensive Cancer Center (LCCC, 
Georgetown University, Washington, DC). The study protocol was approved by Institutional 
Review Boards at both institutions for the following patient samples: women and men aged 
21 years and older; up to three weeks pre- or post-initiation (first day of cycle 1) of the 
current chemotherapy regimen (intravenous or oral agents [IV or PO]) for any stage breast, 
gastric, colon, rectal, small bowel, esophageal, liver, bile duct, and gall bladder cancers; 
prior chemotherapy treatment allowed; U. S. residence; ability to complete computer 
assessments in English (determined by research staff).
Study enrollment and data collection procedures
At both research sites, the Research Coordinator provided a laptop for enrolling patients; at 
LCCC, this laptop was made available upon request for future encounters with patients who 
did not have home internet access. At SCCA, patients without home internet access could 
complete the online fatigue assessments at the SCCA Patient and Family Resource Center. 
Regardless, all patients completed all assessments on-line through the PROMIS Assessment 
Center. Patients could be enrolled up to three weeks pre- or post-initiation (first day of cycle 
1) of the current chemotherapy regimen. The Research Coordinator consented and registered 
each patient on the PROMIS® Assessment Center website [28] [ http://www.nihpromis.org ; 
http://www.assessmentcenter.net/ ] and then trained the patient to complete the first 
PROMIS® assessments online. Timing of the five follow-up monthly assessments was based 
on the date of study registration. Monthly assessments could be completed during the last 
week of the month (multiple log-ins possible during this week). Assessment dates were not 
always synchronized with treatment administration due to treatment delays, which could not 
be identified in time to revise the Assessment Center scheduled assessments.
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Participant incentives—Patients were offered a $50 (total) incentive for their 
participation in the study at two time points: after completion of at least two of the first three 
monthly assessments; similarly, upon completion of at least two of assessments 4, 5, and 6.
Adherence monitoring—The Research Coordinator at each of the two clinical sites 
provided email or telephone reminders at the beginning of the week in which the monthly 
online assessment was available and before the end of online availability if the patient had 
not completed that assessment during the first part of the open period. The Research 
Coordinator also called patients twice during the first three months to identify any 
difficulties accessing or responding via the website.
Patient-reported fatigue and sociodemographic measures
The PROMIS Fatigue CAT [8,24,25,29] currently defaults to a minimum of 4 and a 
maximum of 12 items; this range typically ensures meeting the PROMIS standard error 
precision criterion. [19]. This was the Assessment Center criterion when this study was 
conducted. We did not compare other stopping rules for two reasons: 1) we wanted to use 
the precision criteria currently in use by Assessment Center since this was a model 
assessment approach for measuring PROs in the multi-research site setting; and 2) this 
project was a pilot study and did not have sufficient funding to compare stopping rules or 
evaluate the use of different sets of items from the Fatigue Item Bank. The CAT items were 
administered first, followed by the PROMIS 7a [30] [https://www.assessmentcenter.net/
documents/InstrumentLibrary.pdf] and the FACIT-Fatigue [26,31]. Once a month for six 
months, patients were administered the additional covariate measures: PROMIS® Sleep 
Disturbance 8-item Short Form [32]; one PROMIS® Global Fatigue item [30,33,34]; a 
patient-reported performance status single item [26,35,36]; two questions about patients’ 
physical activity [37,38]; and the global rating of change in fatigue item (assessments 2-6). 
Our pilot test of the Assessment Center's administration of items for this Clinical Study 
confirmed that after answering the PROMIS Fatigue CAT, patients did not receive any 
duplicate items when the PROMIS 7a and the FACIT Fatigue Scale were presented.
This report also includes information for the following clinical status variables for patients 
from both research sites: cancer type, stage, and number of prior chemotherapy regimens. 
The Research Coordinators verified this information (medical records review or 
confirmation provided by clinical staff).
Statistical analyses for assessment of individual change
Precision and reliability of measured change—Measurement theory links an 
observed quantity to an unobserved or latent variable. For this report, we construe the 
observed measure as an individual's mean rate-of-change, or slope, on a PRO fatigue scale 
over six assessments. This pragmatic definition of rate-of-change generalizes the change 
score to multiple assessments, and conveys to clinicians and patients an approximate degree 
of improvement or worsening. In the reliability context, the average rate-of-change for one 
person (as calculated from a chart or an Excel regression line) is the observed variable, and 
the true rate-of-change in fatigue is the unobserved attribute. Imprecision of measured 
change is given by the standard error of the estimated rate-of-change parameter, the expected 
Moinpour et al. Page 5
Qual Life Res. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
deviation of the estimated attribute from the true attribute for one person, the typical amount 
by which the estimated rate-of-change is likely to be off from an individual's true rate-of-
change.
If the error variance in a single assessment  is known, the standard error for an individual 
i's rate-of-change score β1i can be directly calculated as the square root of the sampling 
variance  over the times of assessment Tk. If the 
variance V(β1) of the true rate-of-change in the population is further known, then the 
reliability of the measured rate-of-change can be directly calculated as 
, where the numerator reflects true variance in 
slope across members of the population, and the denominator is the total measured slope 
variance (comprising true plus sampling variability).
In practice, particularly in common clinical monitoring scenarios, the average individual 
rate-of-change is easily estimated but the two variance quantities are unknown. To obtain 
efficient estimates for each of the three PRO measures, we assume a standard linear latent 
growth mixed effects model, with each individual patient i characterized by random effect 
intercept β0i (starting point) and slope β1i (rate of change) terms over the six (t=0 to 5) time 
points of the study: . 
In the population model, the two systematic random effects have means B = (β0,β1)’ and 
unstructured bivariate normal covariance matrix ψ (containing variances for the intercept 
and slope and their covariance), while the unsystematic error is assumed normal and serially 
uncorrelated with constant variance . To enable a more interpretable comparison of the 
precisions, we analyzed standardized scores for the three fatigue measures; this has no effect 
on reliability, relative precision, or other relevant psychometric properties. The key 
hypothesis is evaluated by comparing the relative precision and reliability for the three 
measures as described above and summarized in Table 1 [22,39,40].
For individual monitoring, precision is more important than reliability, but concepts of 
reliability are more familiar. The two indices provide complementary information. Precision 
describes the uncertainty in the measurement (estimation) of an individual's change, while 
reliability also reflects the heterogeneity of the attribute in the (infinite theoretical) 
population. Reliability is a population concept, capturing how variably members of the 
population are systematically changing relative to the total variability (including error) of 
rate-of-change measurements. Our estimate of reliability uses the classical definitional 
formula, which applies to any measured trait, state, or rate attribute β: 
.
While we would prefer to emphasize the salience of precision in individual measurement, it 
is expedient for the purposes of this paper to present the more familiar reliability context as 
well. As noted above [10,12,14-17,22,23] and to our knowledge, PRO measures in use today 
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have not examined the reliability or precision of a measure for assessing rate of change in 
individual patient status.
The average (linear) rate-of-change is indispensably relevant as a summary of individual 
improvement or worsening. It is therefore our primary psychometric target. For simplicity, 
we provisionally assume that the linear trend captures the important systematic change in the 
six-month period. Although not our main focus, we also examine whether the fit of the 
measurement model can be improved by allowing polynomial time trends. Nonlinear trends 
are, however, much more difficult to interpret as summary attributes. As a pragmatic guide, 
we provide an estimate of the minimum number of assessments required for each of the 
measures to yield good measurement (conventionally and somewhat arbitrarily set at .90 for 
individual assessment; reliability depends on the intrinsic true variability, which varies 
across populations) of individual change in fatigue [12].
Results
Table 2 summarizes baseline characteristics for 214 patients who enrolled in this study at the 
two locations with the following percentage of covariate information: SCCA in Seattle 
(62%) and LCCC in Washington, DC (38%). Patient covariate data along with form 
submission rate data were available for 213 of the 214 patients. The mean age was 52 and 
most patients were female (69%). Table 3 lists baseline levels of major covariates collected 
for the study. Baseline fatigue levels for the single-item global item were mostly mild and 
moderate. These patients were physically active with 41% indicating that they walked more 
than an hour during a week; 66% walked at a moderate to fast speed. Sixty-nine percent 
reported good performance status (no symptoms or some symptoms that did not require bed 
rest). Form submission rates for both sites (Table 4) were 100% at baseline (Assessment #1), 
dropping to 67% by Assessment #6. By the 6th Assessment, form submission rates were 
higher for patients enrolled at the SCCA site (71%) vs. the LCCC site (59%). Table 5 shows 
the number of patients receiving treatment at each of the six assessment times at the SCCA. 
The number of patients receiving treatment at the SCCA dropped after the third assessment; 
this was due primarily to shorter courses of chemotherapy. However, 22 SCCA patients 
began radiation treatment after their chemotherapy regimen during the remaining three 
assessment periods and were treated throughout the 6-month assessment period. Eighty-nine 
of the 214 patients (42%) returned to answer monthly assessments after a missed 
assessment, a fairly common experience. Only nine patients at SCCA and ten patients at 
LCCC went off study permanently; reasons for drop-out included death (n=8), ill health 
(n=4), no further verbal contact (n=3), and other (n=4).
Table 6 shows the reliability and precision estimates for measured change in fatigue at the 
individual patient level for each of the three fatigue measures (n=214 patients): PROMIS 
Fatigue CAT, PROMIS 7a, and the FACIT- Fatigue. The sample size for these analyses 
include one additional patient (n = 214) not included in Tables 1-4. The reliabilities 
mentioned in the title of Table 6 reflect the ratio of estimated variance of systematic 
individual differences in rate-of-change (i.e., how people in the population are estimated to 
differ in their individual rates-of-change) to total variance of measured individual differences 
in rate-of-change. These analyses are based on standardized (z-score) scales for either 6 or 3 
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occasions. Column 2 (Population Variance) is an estimate of true rate-of-change variability 
from mixed effects population models with correlated slopes and intercepts. Column 3 
(Sampling Variance) is equivalent to the expected value of the squared discrepancy between 
unbiased maximum likelihood/ordinary least squares (ML/OLS) individual parameter 
estimates, assessed independently one person at a time, and the individual's true value. In the 
special case of linear trend, the sampling variance is the (pooled) measurement error 
variance divided by the sum of an individual's squared time deviations from the mean time 
point. Standard error of measurement results are shown in Column 4, which are square roots 
of respective sampling variances (e.g. √.031143 in Column 3 = the precision estimate of .176 
in column 4). Uncertainties of individual measurements (estimates) of intercept and slope 
depend on the number and pattern of assessments for each person. Inspection of preliminary 
results suggested that patients displayed the most true change variability in the first three 
months, with greater stability thereafter. To allow the most favorable case for reliability to 
emerge, we therefore also ran models restricted to the first three months. Table 6 assumes 
availability of the full number of assessments (either 3 or 6). In practice, fewer assessments 
than this would yield worse precision. See Table 6 notes for additional statistical 
explanations for columns 2-5.
None of the three assessments met conventional benchmarks for excellent reliability (i.e., ≥ 
0.90). Standard errors of measurement of change are also high, indicating large individual 
measurement uncertainty and poor precision of measured change at the individual patient 
level. As expected, each individual's rate-of-change was more precisely measured with six 
assessments than with three. Improved precision did not translate into enhanced scale 
reliability for change, since population rate-of-change variances also decreased with longer 
time spans; months 4-6 evidently introduced a clinical environment in which patients were 
somewhat more similar in how their fatigue changed. With the exception of CAT based on 
six time points, more complex polynomial time models did not notably improve the fit of the 
measurement model; thus, the linear fits of Table 6 are the best summaries of change 
measurement.
Discussion
The results of this study support previous concerns regarding use of PRO measures designed 
for group-level research to monitor change in individual patient status.[12,17,41]. The issues 
raised in these analyses are not necessarily specific to the instruments tested; in fact, we are 
not aware of any fatigue instruments that have demonstrated better performance in 
measuring intra-individual change. Nor are these issues necessarily specific to PRO data. We 
agree with Hahn et al. [15] regarding the need to question the measurement of change in 
clinical and other outcome variables, with respect to how measured change is trusted as 
reliable when making decisions about individual patient status (e.g., responder versus non-
responder).
An additional challenge for clinicians is that most guidelines for interpreting change (e.g., 
minimally important difference, or MID) in PRO measures are based on clinical trials 
involving large numbers of patients in different treatment groups; the cut point for change of 
interest is based on a comparison of averages obtained for each treatment group [42]. The 
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challenge facing clinicians is how to apply findings based on averages for groups of patients 
to the patient facing the clinician [14,17]. Hendrikx et al. [43] reported minimally important 
change cutoff values based on group-level data were not appropriate for monitoring change 
in individual patients due to misclassifications in such change; the authors also noted the 
failure to incorporate how patients value the change and the consequences of changing 
patient care based on these scores. This concern echoes what Donaldson noted in prior work 
[17].
As a practical example, consider the possible use of the PROMIS Fatigue 7a over the course 
of six assessments. This scale and time range featured the best precision of measurement in 
Table 5. (In this example, the low reliability reflects in part the low population variability in 
true change over six assessments.) With a standard error of measurement of .160 (Column 4, 
Linear PROMIS SF, 6 Times), the 95% confidence intervals are roughly +/− .320 about 
individual rate-of-change estimates, which are in units of expected change in standard scores 
per assessment time. A patient estimated to have a rate-of-change of .20 would display a 
cumulative increase of 1.00 standard deviation units over the course of the six assessments, a 
seemingly large effect. Yet the confidence limits on the rate-of-change measurement span .
520 (.200 + .320) to −.120 (.200 − .320). Despite the large measured change estimate, given 
the wide confidence intervals around these estimates (and the fact that the interval includes 
zero), it would not be possible to confidently determine whether the patient was getting 
worse or better or staying the same. Individual assessments require excellent precision, with 
standard errors much smaller than the scores, the estimated attributes.
Despite the low reliabilities in this clinical application, adding additional times of 
assessment, more items/specific types of items, and different analysis methods may address 
the problems we observed. Others (Faes et al, Brandmaier et al) [44,45] have provided 
efficient frameworks for investigating specific reliability and precision scenarios within 
common mixed model contexts. Below we suggest potential solutions, all of which require 
more research.
1) The low reliabilities reflect low rate-of-change variability in the population as 
well as imprecise individual measurement. Precisions (and therefore reliabilities) 
of change measurements may be improved by adding additional assessments. To 
attain excellent measured change reliabilities of .90 in our study, we use the 
Table 6 formula for sampling variance to estimate that the PROMIS CAT would 
need 15 total assessments over the same time range, the PROMIS 7a would need 
14, and the FACIT would need 13, assuming the same underlying psychometrics 
(data not shown). Measurement can be further strengthened by sampling time 
points nearer the ends and the beginnings of longitudinal sequences (so that the 
sum of squared time deviations can be greater).
2) Adding additional items may or may not improve the reliability of change; this 
would depend on the items added. For example, true improvement in 
measurement of change may require the selection of items explicitly for their 
sensitivity to clinical change, as opposed to the typical psychometric 
development approach of maximizing individual differences at single time 
points. Item bank approaches such as those employed for PROMIS CAT and 
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Short Form measures provide an excellent method for identifying such items; 
item banks can also be expanded to include more items that capture change.
3) Empirical Bayes (EB) scoring [46] would yield slightly better reliabilities and 
reduced sampling variabilities, but EB scores are conditionally biased, depend 
on applying weights from a population study, and allow each patient's score to 
be partly determined by the scores of other patients. This is somewhat at odds 
with the simple goal that each patient's change score should reflect only the 
observed data for that patient. Moving to slightly more complex models, 
reliabilities of residual gain scores (regression as opposed to difference) will be 
slightly better than scoring based on pure change [47]. Many other scoring 
variations are possible within a multivariate framework.
Applying any of these recommendations has meaningful implications for the overall 
feasibility of data capture and use in clinical care situations. The data from this study 
suggest that regarding patient/clinician decision making, the confidence limits of individual 
change assessment are so wide that reliable determination of changes in status over time 
may not always be feasible. Adding assessments can improve precision, but only until they 
become prohibitive due to patient burden and retest effects. We suggest designing studies to 
identify or develop precise change measures and the number of assessments needed to yield 
adequate reliabilities given the true variability in the population. For homogeneous 
populations, reliable measurement, whether of traits or of change, may simply not be 
possible. If all chemotherapy patients could show essentially zero fatigue that remained flat 
over time, this would be an ideal result, having zero reliability of measurement but excellent 
precision.
The sample size of 214 is not large for psychometric investigations, but easily exceeds 
conventional rules of thumb [10]. The calculated results involve ratios of variances and are 
essentially unbiased. Precision is more of a concern, though not a major one. This sample 
size yields a standard error of the measurement error variance ranging from 5-10% in these 
scales, a margin too small to meaningfully alter the precision of estimation for the measured 
intercepts and slopes in Table 6. Reliability also involves uncertainty in estimated variances 
of the true slope and intercept attributes, but sampling uncertainty at this level can be 
subsumed under broader questions of how the reliability would change under populations 
having more or less attribute variation. Adding additional patients to such a study would not 
systematically affect our estimates of precision, but adding more numerous and widely 
spaced time points would improve precision. Psychometric study of change should include 
close consideration of the time design of the assessments.
Why did we fail to observe good to excellent reliability? We must first carefully distinguish 
the measured attributes in the reliability models. Conventional reliability studies investigate 
how consistently measurements can distinguish inter-individual differences in an 
unchanging trait or otherwise stable attribute. They assume no underlying change, or that 
everyone changes uniformly. We focused instead on the rate of change as the fundamental 
attribute to distinguish individuals. Conventional models that assume no change are clearly 
inconsistent with better measurement of how patients may be changing, and how reliably 
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and precisely we can measure this change. As previously noted [12,41], measurement of 
change can be much less reliable than static measurement.
Our study informs researchers that current PRO measures may lack the precision required to 
inform decisions about change in individual status, particularly with respect to medical 
decision making. We do not believe this finding is specific to the fatigue instruments used 
here to illustrate the problem. Any number of fatigue measures could have been used in this 
comparison and may well have come to the same conclusion. Indeed, we do not believe this 
issue is specific to PRO, as it may very well be the case in other clinical outcomes used to 
measure and monitor individual change. We suggest this be a subject of study more 
generally, as the field moves into increased tracking of individual change in research and 
clinical applications. Several decades ago, Cronbach and Furby [41] questioned whether we 
should be measuring change at all (particularly with respect to change or difference scores)! 
Current statistical methods now permit rigorous psychometric study of change, so our 
response to Cronbach and Furby's question is enthusiastically affirmative. Meeting rigorous 
psychometric criteria for change measurement, however, remains as challenging today as it 
was decades ago.
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Table 1
Individual change attributes as distributed in the population and measured in a sample
Population Data Model Population (Prior) Distributions Scoring = Estimation of β1i
Description of time 
trajectory for all 
hypothetical members 
of infinite population
Summary characteristics of the hypothetical infinite population (i.e., 
population parameters) that render observed data likeliest
Narrow scope of estimation: Measured time slope and uncertainty 
for person i in the sample
Yij = β0i + β1itij + εij
β0i, β1i ∼ MVN β0, β1 ,
V β0 sym
C β0β1 V β1
εit ∼ N 0, σε
2 β1i = ∑ j = 1
Ti ti j − ti Yi j − Yi ∑ j = 1
Ti ti j − ti
2
(measured time slope for person i)
Conditional sampling variance (and standard error) of rate 
measurement
β1i ∼ N β1i, V β1i ∣ β1i  (unbiased)
σ
β1i = V β1i ∣ β1i
1 2 = σe
2 ∑ j = 1
Ti ti j − ti
2 1 2
Reliability of measured (estimated) rate-of-change
Rxx′ β1 = V β1 V β1 + V β1i ∣ β1i
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Table 2
Patient Characteristics (N=213*)
Age at Diagnosis: Mean (Standard Deviation) 52.40 (10.80)
N (%)
Gender: Female 147 (69)
        Male 66 (31)
Race:
    White 162 (76.1)
    Black or African American 17 (8.0)
    Asian 16 (7.5)
    American Indian/Alaska Native 2 (0.9)
    Native Hawaiian/Pacific Islander 0 (0)
    More than one race 9 (4.2)
    Not Provided (missing) 7 (3.3)
Ethnicity:
    Hispanic or Latino 10 (4.7)
    Not Hispanic or Latino 202 (94.8)
    Not Provided (missing) 1 (0.5)
Education:
    Less than high school 2 (0.9)
    High school graduate or GED 13 (6.1)
    Some college or technical/vocational school 58 (27.2)
    College graduate 59 (27.7)
    Some graduate school 15 (7.0)
    Graduate degree 66 (31.0)
Marital Status:
    Married or living with someone 148 (69.5)
    Divorced 32 (15.0)
    Separated 3 (1.4)
    Widowed 3 (1.4)
    Single (never married) 23 (10.8)
    Not Provided (missing) 4 (1.9)
Employment Status:
    Working full time 95 (44.6)
    Working part time 18 (8.50
    Full-time homemaker or family caregiver 15 (7.0)
    Retired 39 (18.3)
    Unemployed 13 (6.1)
    Student 3 (1.4)
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    Other 12 (5.6)
    More than one answered 17 (8.0)
    Not Provided (missing) 1 (0.5)
# People Living Near You/Can Count On for Help:
    0 7 (3.3)
    1 14 (6.6)
    2 33 (15.6)
    3 to 5 65 (30.5)
    6 to 9 29 (13.6)
    10 or more 64 (30.0)
    Not Provided (missing) 1 (0.5)
Research Site Location:
    Seattle Cancer Care Alliance 132 (62.0)
    Lombardi Comprehensive Cancer Center 81 (38.0)
Cancer Type:
    Breast 89 (41.8)
    Colon 79 (37.1)
    Rectal 17 (8.0)
    Colorectal 1 (0.5)
    Small Bowel 2 (0.9)
    Gastric 7 (3.3)
    Esophageal 7 (3.3)
    Liver 5 (2.3)
    Bile Duct 4 (1.9)
    Gall Bladder 2 (0.9)
Cancer Stage:
    I 15 (7.0)
    II 47 (22.1)
    III 47 (22.1)
    IV 103 (48.4)
    Not Provided (missing) 1 (0.5)
# Prior Chemo Regimens:
    0 101 (47.4)
    1 30 (14.1)
    2 or more 23 (10.8)
    Not Provided (missing) 59 (27.7)
*Clinical data were not available for one patient.
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Table 3
Baseline Covariate Status (n=213*)
N (%)
    Global Rating of Fatigue
        None 30 (14.1)
        Mild 85 (39.9)
        Moderate 73 (34.3)
        Severe 22 (10.3)
        Very severe 2 (0.9)
        Not Provided (missing) 1 (0.5)
Physical Activity
    Minutes/week walking
        Never takes walks 21 (9.9)
        About 15 minutes 16 (7.5)
        About 30 minutes 40 (18.8)
        About 45 minutes 25 (11.7)
        About 60 minutes 22 (10.3)
        Longer than one hour 87 (40.8)
        Not Provided (missing) 2 (0.9)
    Usual walking speed
        Never takes walks 13 (6.1)
        Very slowly 8 (3.8)
        Slowly 36 (16.9)
        Moderately 111 (52.1)
        Fast 29 (13.6)
        Very fast 14 (6.6)
        Not Provided (missing) 2 (0.9)
    Patient-Rated Performance Status
        Normal activity without symptoms 56 (26.3)
        Some symptoms, but not required bed rest during waking day 93 (43.7)
        Require bed rest for less than 50% of waking day 47 (22.1)
        Require bed rest for more than 50% of waking day 14 (6.6)
        Unable to get out of bed 0 (0)
        Not Provided (missing) 3 (1.4)
*Covariate data were not available for one patient
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Table 4
Internet Assessment Submission Rates
Assessment groups (N) All LCCC SCCA
Assessment 1 Completed 213 81 132
Assessment 1 missed 0 0 0
Assessment 1 Off study 0 0 0
Assessment 2 Completed 154 60 94
Assessment 2 missed 49 16 33
Assessment 2 Off study 10 5 5
Assessment 3 Completed 145 53 92
Assessment 3 missed 53 21 32
Assessment 3 Off study 15 7 8
Assessment 4 Completed 136 47 89
Assessment 4 missed 59 25 34
Assessment 4 Off study 18 9 9
Assessment 5 Completed 135 46 89
Assessment 5 missed 59 25 34
Assessment 5 Off study 19 10 9
Assessment 6 Completed 129 42 87
Assessment 6 missed 65 29 36
Assessment 6 Off study 19 10 9
Assessment 1 Submission Rate 100 100 100
Assessment 2 Submission Rate 75.86 78.947 74.02
Assessment 3 Submission Rate 73.23 71.622 74.19
Assessment 4 Submission Rate 69.74 65.278 72.36
Assessment 5 Submission Rate 69.59 64.789 72.36
Assessment 6 Submission Rate 66.49 59.155 70.73
Submission Rate = Completed / Eligible to complete (completed + missed); LCCC = Lombardi Comprehensive Cancer Center; SCCA = Seattle 
Cancer Care Alliance. Submission rate data were available only for patients who completed the full set of measures; one patient did not complete 
the covariate data.
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Table 5
Number of SCCA Patients Receiving Chemotherapy or Chemotherapy + Radiation at Each Assessment Time 
Point
# PT on TX 
A1
# PT on TX 
A2
# PT on TX 
A3
# PT on TX 
A4
# PT on TX 
A5
# PT on TX 
A6
# PT off 
study
Chemo + RT 132 117 97 82 68 53 9
# PT lost at each A 15 20 15 14 15
PT = Patient; TX = Treatment ; Chemo = Chemotherapy [All types: Infusion and oral chemo; Chemo + RT (22 SCCA patients began RT post-
chemo); Infusion + oral + RT]; RT= Radiation Therapy; A = Assessment
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Table 6
Estimated Reliabilities of Measured Changea in Three Fatigue Measures
N = 214 Population Variancec Sampling Varianced Standard error of 
Measurementd
Reliability of Measuremente
LINEAR CAT, 6 TIMES
Intercept T0=0 .414636 .285474 .534 .592
(Intercept T0=2.5) (.410391) (.090826) (.301) (.819)
Linear Slope .017738 .031143 .176 .363
Within Person .544996 |i,t .738238 |i,t
Single assessmentf .455 |t
QUADRATIC CAT, 6 TIMES
Intercept T0=0 .494551 .387915 .623 .560
Linear Slope|T0=0b .103431 .343221 .586 .232
Quadratic .004427 .012649 .112 .259
Within Person .472245 |i,t .687 |i,t
Single assessment .528 |t
LINEAR CAT, 3 TIMES
Intercept T0=0 .651514 .33248 .577 .659
Linear Slope .103597 .19949 .447 .342
Within Person .38972 |i,t .624 |i,t
Single assessment .610 |t
LINEAR PROMIS SF, 6 
TIMES
Intercept T0=0 .533152 .235924 .486 .693
Linear Slope .017712 .025737 .160 .408
Within Person .450401 |i,t .671 |i,t
Single assessment .550 |t
LINEAR PROMIS SF, 3 
TIMES
Intercept T0=0 .830349 .219962 .469 .791
Linear Slope .150426 .131977 .363 .533
Within Person .263954|i,t .490 |i,t
Single assessment .736 |t
LINEAR FACIT, 6 TIMES
Intercept T0=0 .511570 .254444 .504 .668
Linear Slope .023577 .027758 .167 .459
Within Person .485757|i,t .697 |i,t
Single assessment .514 |t
LINEAR FACIT, 3 TIMES
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N = 214 Population Variancec Sampling Varianced Standard error of 
Measurementd
Reliability of Measuremente
Intercept T0=0 .693272 .252123 .502 .733
Linear Slope .136008 .151274 .389 .473
Within Person .302547|i,t .550 |i,t
Single assessment .697 |t
Standard errors and reliabilities for Intercept depend on the time for which T=0. Even though intercept is defined to occur at one (possibly 
hypothetical) time point, its estimation uses information from all time points. Taken above as T=0 baseline, Intercept is interpreted as initial status. 
As T→ Mean (Time), the Intercept behaves more like the mean score across times, which can be highly reliable, though irrelevant for change. An 
example is provided for the linear CAT model with 6 assessment points. Setting T=2.5, near the middle of the time range, yields highly reliable 
Intercept measurement, but properties of the slope are unaffected.
a
Ratio of estimated variance of systematic individual differences in rate-of-change to total variance of measured individual differences in rate-of-
change using model-based pooled estimates of within-person error. To make descriptive comparisons across scales easier, the analyses are based on 
standardized (z-score) scales over all time points available (either 6 or 3 occasions). This linear transformation has no effect on reliability 
calculations.
b
Instantaneous rate-of-change at T=0 baseline.
c
ML (maximum likelihood) estimate of true variability from mixed effects population models with correlated slopes and intercepts.
d
Equivalent to expected value of squared discrepancy between unbiased ML/OLS (ordinary least squared) individual parameter estimate, assessed 
independently one person at a time, and individual's true value. Sampling variance given collectively by diag(Λ′Φ−1Λ)−1, where Φ is the within-
person sampling (measurement) error, an estimated population parameter, and Λ contains the constant, linear, and quadratic time contrasts. 
Standard errors are square roots of respective sampling variances. Uncertainties of individual measurements (estimates) of intercept and slope 
depend on number and pattern of assessments for each person. The table assumes availability of the full number of assessments (either 3 or 6). 
Standard errors increase, and reliabilities decrease, with fewer assessments. The square root of the within-person residual error is the model-based 
estimate of the scale's standard error of measurement at any given time point. For example, under the linear 6-assessment model the CAT has an 
estimated scale standard error of .742 in standardized units. This defines the typical error of measurement error expected in one assessment of one 
individual. The 95% confidence intervals for the single assessment would be approximately +/− (2*.742) = +/− 1.484 standardized units.
e
Reliabilities defined classically as ratios of true population variance (Ψ) to measured variance. The measured variance is the sum of true variance 
and the sampling variance. The reliability is then ρbb′ = ψb / (ψb + diagb(λb′Φ−1λb)−1), where b is the intercept or slope (or quadratic 
coefficient).
fWith standardized measures, the model-based estimate of the reliability of a single assessment is one minus the residual or within-person error, 
equivalent to one minus the squared standard error of measurement of the scale. The term t refers to a single assessment at any single time.
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